GSP timeline
Every GSP batch the index holds, newest manufacture date first, with the supplier's declared purity beside the median of the index's independent observations of the same lot.
| Lot | Compound | Manufactured | Quarter | Tests | Independent median | Spread (pp) | COA purity | Divergence (pp) | |
|---|---|---|---|---|---|---|---|---|---|
| GSP-2607-N3316 | L-Glutathione (reduced) | 20 Jul 2026 | 2026-Q3 | 9 | 98.57 | 0.52 | 98.70 | +0.13 | |
| GSP-2605-K2548 | ARA-290 | 11 May 2026 | 2026-Q2 | 8 | 99.58 | 0.76 | 99.90 | +0.32 | |
| GSP-2604-X3197 | TB-500 | 02 Apr 2026 | 2026-Q2 | 2 | 98.85 | 0.00 | 98.45 | -0.40 | |
| GSP-2603-E2342 | Survodutide | 24 Mar 2026 | 2026-Q3 | 7 | 98.43 | 1.37 | 98.09 | -0.34 | |
| GSP-2601-S2590 | Semaglutide | 08 Jan 2026 | 2026-Q2 | 2 | 99.27 | 0.05 | 99.76 | +0.49 | |
| GSP-2512-H2477 | Selank | 25 Dec 2025 | 2026-Q1 | 1 | 99.79 | n<2 | 99.88 | +0.09 | |
| GSP-2512-E2121 | BPC-157 | 15 Dec 2025 | 2026-Q2 | 4 | 99.01 | 0.58 | 99.13 | +0.12 | |
| GSP-2512-N3107 | PT-141 (Bremelanotide) | 03 Dec 2025 | 2026-Q2 | 4 | 99.62 | 0.73 | 99.48 | -0.14 | |
| GSP-2512-H2024 | Semaglutide | 01 Dec 2025 | 2026-Q2 | 7 | 98.61 | 1.05 | 98.64 | +0.03 | |
| GSP-2511-C2613 | SLU-PP-332 | 08 Nov 2025 | 2025-Q4 | 1 | 99.50 | n<2 | 99.50 | 0.00 | |
| GSP-2511-Y3244 | TB-500 | 02 Nov 2025 | 2026-Q2 | 1 | 99.34 | n<2 | 99.34 | 0.00 | |
| GSP-2508-F2325 | GHRP-6 | 30 Aug 2025 | 2025-Q3 | 6 | 99.54 | 0.55 | 99.47 | -0.07 | |
| GSP-2508-S2438 | TB-500 | 17 Aug 2025 | 2026-Q1 | 1 | 99.38 | n<2 | 99.32 | -0.06 | |
| GSP-2508-H2704 | BPC-157 | 14 Aug 2025 | 2026-Q1 | 5 | 98.90 | 0.32 | 99.09 | +0.19 | |
| GSP-2508-Y2817 | PT-141 (Bremelanotide) | 10 Aug 2025 | 2025-Q4 | 1 | 99.40 | n<2 | 99.57 | +0.17 | |
| GSP-2508-U2933 | Afamelanotide | 09 Aug 2025 | 2025-Q4 | 7 | 99.40 | 0.23 | 99.61 | +0.21 | |
| GSP-2507-A3112 | NAD+ | 15 Jul 2025 | 2025-Q3 | 4 | 99.10 | 0.59 | 99.52 | +0.42 | |
| GSP-2506-P3349 | Liraglutide | 23 Jun 2025 | 2025-Q4 | 8 | 99.06 | 0.96 | 99.01 | -0.05 | |
| GSP-2506-D1645 | Oxytocin | 16 Jun 2025 | 2025-Q3 | 1 | 98.90 | n<2 | 99.01 | +0.11 | |
| GSP-2505-E2912 | Liraglutide | 28 May 2025 | 2025-Q3 | 2 | 98.68 | 0.01 | 99.21 | +0.53 | |
| GSP-2505-S3107 | AOD-9604 | 13 May 2025 | 2025-Q4 | 1 | 98.39 | n<2 | 98.50 | +0.11 | |
| GSP-2503-R3069 | BPC-157 | 25 Mar 2025 | 2025-Q3 | 9 | 99.51 | 0.78 | 99.16 | -0.35 | |
| GSP-2503-B2806 | NAD+ | 20 Mar 2025 | 2025-Q3 | 12 | 99.90 | 0.73 | 99.68 | -0.22 | |
| GSP-2501-G2894 | Tesamorelin | 24 Jan 2025 | 2025-Q1 | 2 | 98.71 | 0.45 | 98.74 | +0.03 | |
| GSP-2501-J1983 | Thymosin α1 | 19 Jan 2025 | 2025-Q2 | 9 | 98.78 | 1.30 | 98.86 | +0.08 | |
| GSP-2501-R1969 | MK-677 (Ibutamoren mesylate) | 18 Jan 2025 | 2025-Q1 | 11 | 99.51 | 0.74 | 99.59 | +0.08 | |
| GSP-2501-R2981 | Semaglutide | 14 Jan 2025 | 2025-Q1 | 12 | 98.50 | 0.87 | 98.62 | +0.12 | |
| GSP-2411-B2043 | Retatrutide | 29 Nov 2024 | 2025-Q2 | 8 | 97.75 | 0.80 | 98.07 | +0.32 | |
| GSP-2411-J3226 | NAD+ | 15 Nov 2024 | 2025-Q2 | 1 | 99.31 | n<2 | 99.01 | -0.30 | |
| GSP-2411-S3103 | Retatrutide | 14 Nov 2024 | 2025-Q1 | 5 | 97.87 | 0.48 | 97.87 | 0.00 | |
| GSP-2411-L1648 | AOD-9604 | 10 Nov 2024 | 2025-Q2 | 4 | 99.13 | 0.54 | 98.30 | -0.83 | |
| GSP-2411-J2886 | Vilon | 06 Nov 2024 | 2025-Q1 | 1 | 99.00 | n<2 | 99.31 | +0.31 | |
| GSP-2410-U3278 | LL-37 | 03 Oct 2024 | 2024-Q4 | 8 | 98.12 | 0.56 | 97.93 | -0.19 | |
| GSP-2408-K2005 | Semax | 31 Aug 2024 | 2024-Q4 | 3 | 99.82 | 0.52 | 99.90 | +0.08 | |
| GSP-2405-W2517 | Semaglutide | 08 May 2024 | 2024-Q2 | 15 | 98.90 | 1.05 | 98.93 | +0.03 | |
| GSP-2404-P1970 | Semax | 29 Apr 2024 | 2024-Q3 | 13 | 99.93 | 0.21 | 99.88 | -0.05 | |
| GSP-2402-G2914 | BPC-157 | 14 Feb 2024 | 2024-Q1 | 2 | 99.02 | 0.02 | 98.64 | -0.38 | |
| GSP-2401-W1769 | TB-500 | 12 Jan 2024 | 2024-Q2 | 12 | 98.93 | 0.72 | 99.54 | +0.61 | |
| GSP-2311-C2103 | Hexarelin | 11 Nov 2023 | 2024-Q1 | 1 | 99.10 | n<2 | 99.41 | +0.31 |